| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sands Capital Life Sciences Pulse Fund II, L.P. | 11% | -26% | $26,037,930 | +$4,137,930 | 13,018,965 | +19% | Sands Capital Life Sciences Pulse Fund II, L.P. | 31 Dec 2025 |
| PERCEPTIVE ADVISORS LLC | 10% | $25,633,286 | 12,816,643 | Perceptive Advisors LLC | 31 Dec 2025 | |||
| ADAR1 Capital Management, LLC | 9.9% | 0% | $25,384,774 | +$9,909,386 | 12,692,387 | +64% | ADAR1 Capital Management GP, LLC | 31 Dec 2025 |
| Fairmount Funds Management LLC | 9.9% | 0% | $24,922,202 | +$10,885,052 | 12,461,101 | +78% | Fairmount Funds Management LLC | 31 Dec 2025 |
| Nantahala Capital Management, LLC | 5.7% | -23% | $14,075,832 | +$3,478,584 | 7,037,916 | +33% | Nantahala Capital Management, LLC | 31 Dec 2025 |
| Trails Edge Capital Partners, LP | 5.1% | $9,525,057 | 6,145,198 | Trails Edge Capital Partners, LP | 23 Dec 2025 | |||
| ARMISTICE CAPITAL, LLC | 5% | $7,975,554 | 3,529,006 | Armistice Capital, LLC | 31 Dec 2024 |
As of 31 Dec 2025, 73 institutional investors reported holding 106,415,262 shares of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT). This represents 83% of the company’s total 128,205,929 outstanding shares.
The largest institutional shareholders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) together control 81% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Sands Capital Alternatives, LLC | 10% | 13,018,965 | +19% | 5.1% | $26,688,878 |
| Soleus Capital Management, L.P. | 8.5% | 10,875,000 | +72% | 0.95% | $22,293,750 |
| Fairmount Funds Management LLC | 6.7% | 8,625,000 | +41% | 1.3% | $17,681,250 |
| ADAR1 Capital Management, LLC | 6.3% | 8,063,949 | +54% | 1.2% | $16,531,095 |
| Trails Edge Capital Partners, LP | 4.8% | 6,178,124 | 0% | 3.1% | $12,665,154 |
| Blackstone Inc. | 4.6% | 5,938,276 | +125% | 0.05% | $12,173,466 |
| Siren, L.L.C. | 4.6% | 5,850,000 | 0.36% | $11,992,500 | |
| PERCEPTIVE ADVISORS LLC | 4.2% | 5,421,568 | 0% | 0.2% | $11,114,214 |
| Commodore Capital LP | 4.2% | 5,397,488 | 0% | 0.74% | $11,064,850 |
| VANGUARD GROUP INC | 3.6% | 4,558,604 | +39% | 0% | $9,345,138 |
| Squadron Capital Management LLC | 3.3% | 4,225,000 | 0% | 3.9% | $8,661,250 |
| Nantahala Capital Management, LLC | 3.1% | 3,929,292 | +79% | 0.48% | $8,055,049 |
| Saturn V Capital Management LP | 3% | 3,856,799 | 1.5% | $7,906,438 | |
| Spruce Street Capital LP | 2.8% | 3,581,603 | 0% | 2.4% | $7,342,286 |
| BlackRock, Inc. | 2.6% | 3,305,574 | +7.5% | 0% | $6,776,427 |
| Stonepine Capital Management, LLC | 1.8% | 2,348,147 | +219% | 3.8% | $4,813,701 |
| Integral Health Asset Management, LLC | 1.4% | 1,750,000 | 0.18% | $3,587,500 | |
| Kalehua Capital Management LLC | 1.4% | 1,750,000 | 0% | 3.6% | $3,587,500 |
| AMERIPRISE FINANCIAL INC | 1.1% | 1,376,395 | 0% | $2,821,610 | |
| CITADEL ADVISORS LLC | 0.97% | 1,243,630 | +1635% | 0% | $2,549,441 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.88% | 1,128,239 | +1.4% | 0% | $2,313,006 |
| Exome Asset Management LLC | 0.47% | 600,000 | 0.62% | $1,230,000 | |
| STATE STREET CORP | 0.43% | 554,849 | +9.3% | 0% | $1,137,440 |
| Seven Fleet Capital Management LP | 0.42% | 533,648 | 0% | 0.84% | $1,093,978 |
| NORTHERN TRUST CORP | 0.25% | 322,720 | -14% | 0% | $661,576 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 106,415,262 | $218,151,569 | +$72,128,708 | $2.05 | 73 |
| 2025 Q3 | 54,964,771 | $89,043,214 | +$712,913 | $1.62 | 53 |
| 2025 Q2 | 54,512,097 | $106,299,597 | +$5,482,917 | $1.95 | 48 |
| 2025 Q1 | 51,462,756 | $112,702,942 | +$3,027,389 | $2.19 | 47 |
| 2024 Q4 | 50,059,308 | $162,691,896 | +$161,164,562 | $3.25 | 31 |
| 2024 Q3 | 860,232 | $1,118,330 | +$30,199 | $1.30 | 11 |
| 2024 Q2 | 836,496 | $1,021,038 | +$723,392 | $1.21 | 12 |
| 2024 Q1 | 205,558 | $443,782 | -$62,190 | $2.16 | 12 |
| 2023 Q4 | 235,004 | $298,925 | -$271,105 | $1.27 | 11 |
| 2023 Q3 | 429,662 | $597,627 | -$496,803 | $1.39 | 13 |
| 2023 Q2 | 747,138 | $2,693,647 | +$2,394,678 | $3.61 | 14 |
| 2023 Q1 | 82,817 | $54,460 | +$54,460 | $0.66 | 1 |